Correspondence 0001493152-23-024207 from ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc.
Date: July 11, 2023 · CIK: 0001859007 · Accession: 0001493152-23-024207
AI Filing Summary & Sentiment
Show Raw Text
CORRESP
1
filename1.htm
A.G.P./ALLIANCE
GLOBAL PARTNERS
590
Madison Avenue 28th Floor New York,
New
York 10022
July
11, 2023
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re:
ZyVersa Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333- 272657 (the “Registration Statement”)
Ladies
and Gentlemen:
Reference
is made to our letter filed as correspondence via EDGAR on July 7, 2023, in which we, as the sole placement agent, requested the
acceleration of the effective date of the above-captioned Registration Statement for July 10, 2023 at 5:00 p.m. Eastern Time, in accordance
with Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as
amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw
our request for acceleration of the effective date.
Very truly yours,
A.G.P./ALLIANCE GLOBAL PARTNERS
By:
/s/
Thomas Higgins
Name:
Thomas
Higgins
Title:
Managing Director